Top Markets
Coin of the day
Valerio Therapeutics S.A. Valerio Therapeutics S.A.

Valerio Therapeutics S.A.

ALVIO
주식 순위 #14060
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A.... Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. The company's offerings include Beleodaq, an approved medication for peripheral T-cell lymphoma. Their development pipeline features AsiDNA, which is progressing through Phase 1 clinical trials for metastatic melanoma and is also being evaluated for relapsed ovarian cancer through a research collaboration with Gustave Roussy. Furthermore, Valerio Therapeutics is advancing OX401, a preclinical program targeting DNA damage response and immuno-oncology, along with its proprietary platON decoy oligonucleotide platform. The firm also holds a licensing agreement with Acrotech Biopharma LLC.
주가
$0.88012714
마지막 동기화: 2026-08-31
시가총액
$439.58M
변동 (1일)
-4.01%
변동 (1년)
1,131.97%
국가
FR
거래 Valerio Therapeutics S.A. (ALVIO)

카테고리

Valerio Therapeutics S.A. (ALVIO)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Valerio Therapeutics S.A.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Valerio Therapeutics S.A.의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH